Nachrichten zur Hofseth BioCare ASA Aktie

The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the companys premises at Keiser Wilhelms…

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today…

Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC…

HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full…

HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study…

Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting…

Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items…

Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 14 December…

Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 13 December…

The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth…

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act…

Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth…

The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last…

The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and…

HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required…

Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at…

HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen…

Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project")…

The first quarter of 2023 shows a very good development for HBC. Revenues came in at NOK 44m vs NOK…

Hofseth BioCare ASA held its Annual General Meeting on 28 April 2023. 253,351,609 shares, amounting to 64.13 per cent of…

Reference is made to the notice from Hofseth BioCare ASA (the "Company") for an annual general meeting to be held…

The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2022 and the Company has…

Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare…

Christoph Baldegger, primary insider and member of the board of directors in Hofseth BioCare ASA ("HBC") has today purchased 100,000…

In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last…

Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at…

The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and…